Comparative bioavailability of two oral formulations of ranitidine

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 1, 2006, Pages 23-27

  Flores Murrieta, Francisco J ^a,b   Toledo, Alejandra ^b   Carrasco Portugal, Miriam del Carmen ^a,b   Reyes García, Gerardo ^a   Rodríguez Silverio, Juan ^a,b   Medina Santillán, Roberto ^a   Herrera, Jorge E ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

Author keywords

Azantac; Dissolution profile; Midaven; Ranitidine

Indexed keywords

RANITIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW TEMPERATURE PROCEDURES; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MEXICO; RANITIDINE; SOLUBILITY; THERAPEUTIC EQUIVALENCY;

EID: 31744444301     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.477     Document Type: Article

References (13)

1. Strum WB. Ranitidine. JAMA 1983; 250: 1894-1896.
2. Zeldis JB, Friedman LS, Isselbacher KJ. Ranitidine: a new H2-receptor antagonist. N Engl J Med 1983; 309: 1368-1373.
3. Castañeda-Hernández G, Flores-Murrieta FJ, Granados-Soto V, et al. Pharmacokinetics of oral ranitidine in Mexicans. Arch Med Res 1996; 27: 349-352.
4. Franco C, Flores-Murrieta FJ, Castañeda-Hernández G. Pharmacokinetic-pharmacodynamic modeling of oral ranitidine: implications in efficacy and safety. Proc West Pharmacol Soc 1997; 40: 107-109.
5. Farmacopea de los Estados: Unidos Mexicanos, 7a Edición, Tomo II. México, 2000; 1743.
6. Norma Oficial Mexicana NOM-177-SSA1-1998. Diario Oficial de la Federación. Tomo DXLVIII No. 4. Mayo 7 de 1999; 44-67.
7. Yu LX, Wang JT, Hussain AS. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. AAPS Pharm Sci 2002; 4: 1-5.
8. Cappola ML. A better dissolution method for ranitidine tablets USP. Pharm Dev Technol 2001; 6: 11-17.
9. Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and Applications, 3rd edn. Lea & Febiger: Philadelphia, London, 1995.
10. Schuirmann DJ. A comparison of the two one-sided tests procedure, the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
11. Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1990; 39: 5-10.
12. Steinijans VW, Hauschke D, Jonkman JHG. Controversies in bioequivalence studies. Clin Pharmacokinet 1992; 22: 247-253.
13. Blume HH, Schug BS. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? Eur J Pharm Sci 1999; 9: 117-121.